Top novel drug approvals: February 2019
Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP...
List view / Grid view
Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP...
12 January 2017 | By Niamh Marriott, Digital Editor
Topline results from this Phase IIb study to treat children with RSV with inhaled ALX-0171 are expected in the second half of 2018...
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Acquired TTP is an acute, ultra-rare, life-threatening blood clotting disorder in which uncontrolled platelet aggregation and microclot formation cause...
4 May 2016 | By Victoria White, Digital Content Producer
The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation...
11 February 2016 | By Victoria White
Results from Ablynx’s worldwide Phase II TITAN study with caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) have been published...
27 August 2015 | By Nick Jackson
Ablynx has announced its business update and results for the six-month period ending 30 June 2015...